BioArctic AB (publ) BIOA-B.ST
Nasdaq Stockholm · Healthcare · Biotechnology
307.20 SEK
+0.7%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for BioArctic
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 228 | 616 | 257 | 1,999 |
| EBITDA | 4 | 284 | −179 | 1,270 |
| Net income | −11 | 229 | −177 | 1,022 |
| Balance sheet | ||||
| Equity | 786 | 1,047 | 895 | 1,967 |
| Total debt | 10 | 5 | 54 | 44 |
| Cash | 805 | 612 | 513 | 1,040 |
| Net debt | −795 | −607 | −459 | −996 |
| Ratios and per share | ||||
| EBITDA margin | 1.8% | 46.1% | −69.5% | 63.6% |
| Profit margin | −4.9% | 37.2% | −68.8% | 51.1% |
| Return on equity | −1.4% | 21.9% | −19.8% | 52.0% |
| Earnings/share (SEK) | −0.13 | 2.60 | −2.00 | 11.53 |
| Book value/share (SEK) | 8.92 | 11.85 | 10.13 | 22.19 |
| Shares outstanding (M) | 88 | 88 | 88 | 89 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 26.6 |
| P/B | 13.8 |
| EV / EBITDA | 20.6 |
| Net debt / EBITDA | −0.8 |
| Return on equity | 52.0% |
| Profit margin | 51.1% |
| Beta 1Y | 0.99 |
| Revenue growth 1Y | +676.8% |
| Revenue CAGR 3Y | +106.1% |
| ROE avg. 3Y | 18.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 2.00 |
Not investment advice. Figures may contain errors from the data source.